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Introduction
I ???????????????????????????????????????????????????????-testinal (GI) diseases, according to the reports on the burden 
of GI diseases in the United States (USA).1 Although its mor-
tality is low, its onset during early adulthood and its chronicity as 
???????????????????????????????????????????????????????????????????????
the patients and heavy burden on the health care system with huge 
cost. For example, the second most commonly prescribed drug by 
GI specialists in USA was Mesalazin after proton pump inhibitors 
and H2-blockers.2 According to the Global burden of diseases 
(GBD) study, 10,576,000 people across the world were affected 
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by IBD that led to 3,729,100 disability-adjusted life years world-
wide in 2013.3,4  Furthermore, GBD study reported that 51,200 
deaths  were  attributed to IBD in 2013.5  A nationwide study in 
USA showed that the mean annual cost for each patient with 
Crohn’s disease (CD) and ulcerative colitis (UC) were 8,265 $ and 
5,066 $ respectively.6  It was also estimated that work disability 
due to IBD in Europe cost about 4.6 – 5.6 billion Euros yearly.7 
IBD was known to be more prevalent and incident in North 
America and North-West of Europe compared with Asia and Afri-
ca.8 Incidence of IBD in Faroe Island is reported to be the highest 
(83.1 per 100,000) in the world.9 Also the highest reported preva-
lence in the world was based on a national study in USA (908 per 
100,000).10 While in a comprehensive systematic review it was 
reported that the incidence and prevalence of IBD are  increasing 
almost in all parts of the world,11 some recent studies reported de-
creasing or stabilizing incidence of IBD in western countries,12–14 
in contrast to a considerable increase in IBD prevalence in Asia 
and Eastern Europe.7,15–17 
IBD in Iran as a Middle-Eastern middle-income country with 
rapid socioeconomic changes seems to have similar trends. Previ-
ous epidemiologic studies of IBD in Iran did not report its inci-
dence and prevalence nationally. Moreover, only two population-
based studies reported their cases at provincial level.18,19 Naghavi 
et al. estimated that the burden of GI diseases ranked 7th among all 
other diseases at national level in 2003,20 but the burden of each 
GI disease has not been calculated yet. Therefore, calculating the 
national incidence and prevalence of IBD and its burden seems to 
be an essential step in facing the IBD epidemic in the country. In 
this study, we aimed to evaluate the prevalence and incidence of 
IBD and its trend in Iran at national and subnational level from 
1990 up to 2012 as part of recent ongoing studies on the burden 
of GI disease in Iran,21 which can help health policy makers for 
better health planning and providing an opportunity for further 
research on understanding the environmental risk factors of this 
disease in Iran.
Materials and Methods
Study population
Iran is one of the largest and most populated countries in Mid-
dle East (1.65 million sq. km area) with a substantially increased 
population during the 2nd half of the 20th century approaching 78.5 
million in 2014. It is a country with diverse ethnicities, more than 
10 ethnic backgrounds, cemented by the Persian language and 
????????? ?????????????????????????????????????????????????????????????
urban growth rates in the world (from 27 to 71%). More than two 
thirds of the population is under the age of 30, with a life expec-
tancy of 73 years for men and 76 years for women. The literacy 
rate is 86%. It has 31 provinces with the heterogeneous population 
distribution. There are 353 Gastroenterologists in clinical practice 
in the country. More than 60% of these gastroenterologists are liv-
ing in Tehran and ten big provincial capital cities. The majority of 
IBD patients are treated in tertiary care centers in provincial capi-
tals and many of them are referred to Tehran as the capital with 
higher skilled GI specialists and better medical services. 
?????????????????????????????
Diagnosis of IBD was based on a combination of clinical, radio-
???????????????????????????????????????????????????????????????
K50 for UC, K51 for CD, and K52 for intermediate colitis (IC) ac-
cording to international coding of diseases version 10. We catego-
rized age in groups of 5-year intervals. For estimating incidence, 
we considered age at diagnosis equal to age at disease onset.
Data sources
Systematic review
We conducted a systematic review of English (PubMed, Web of 
Science, and Scopus) and Persian (IronDoc, Barakat knowledge 
network system, and SID) databases on incidence, prevalence, 
and epidemiology of IBD in Iran. Literature search was con-
ducted up to 9/15/2015. The search terms were chosen accord-
ing to the MeSH terms of the national library of medicine in the 
USA (supplementary Table 1). By evaluating the titles, abstracts, 
and full texts, we included all articles except those not related to 
IBD, not conducted in Iran, case reports or animal studies, done 
on age below 15, or conducted before 1990. Full texts were then 
collected and only those cases-series, reviews, or population-base 
studies, which reported the number of IBD patients with their de-
mographic features, were included (Figure 1). 
Outpatient data
For collecting outpatient data, a questionnaire including name, 
father’s name, age, sex, place of living (at the provincial level), 
year of IBD diagnosis, and subtypes of IBD (UC, CD, IC) was 
used. We also managed to call most gastroenterologists in active 
clinical practice and invited them to participate and send us the 
data. All colleagues who shared their patients’ data with us had 
used accurate and up to date criteria for diagnosis of IBD and 
most of their patients were under clinical care and follow up for 
??????????????????? ?????????????????????????????????????????????
17 provinces. Patients who were younger than 15 years old were 
excluded from our study as the study was designed for adults. 
Also, those patients who were diagnosed before 1990 were ex-
???????????????????????????????????????????????????????????????
patient, duplicates were found and excluded by checking similar-
ity in name, family name, father’s name, and age. After exclud-
ing duplicates, only 11,000 cases remained in our database. To 
prevent false effect on our modeling, data of patients who referred 
to other provinces but lived in provinces with no local data were 
also omitted (Figures 2 and 3). 
Statistical Analyses
We calculated the crude prevalence and incidence rate per 
100,000 for outpatient data. The denominator was the national 
population at risk (adults older than 15 years old). The average 
annual incidence of IBD, UC, and CD were also calculated. We 
obtained national population data by sex, age group, and province 
up to 2012 from the Statistical Center of Iran and used it as the 
denominator for calculating incidence and prevalence. 
The available dataset for analyses consisted of 543 crude inci-
dence rates for two IBD types including UC and CD. We used 
attributed rates for all ages and both sex combinations from 1990 
to 2012. The frequencies of incidence rates based on the number 
of provinces in each year are displayed in supplementary Table 2. 
For example, we had 13 provinces with incidence rates data for 
CD and 9 provinces for UC in 2000. Also, we had 44 prevalence 
rates at national level for two IBD types from 1990 to 2011.  
Since prevalence rates were available at national level, we had 
to use a statistical method for adjusting prevalence rates at subna-
tional level. Therefore, we applied a regression model for preva-
lence rates on existing national incidence rates in each year that 
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Mesh Terms ???????????????????????????
Entry Terms
?????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
Ileitis, Regional; 
Colitis, Granulomatous;
 Enteritis, Granulomatous
Enteritis, Regional
PubMed Search terms ????????????????????????????????????????? ??????????????????????????????????????????????????????????????????????????????????????????????????????????????????????
ISI, Scopus Search 
Terms 
??????????????????????????????????????????????????? ??????????????????????????????????????????????????????????????????
Ulcerative Colitis OR  Crohn’s Disease OR Ileocolitis  OR  Ileitis, Terminal OR Ileitis, Regional OR Colitis, Granulomatous OR  
Enteritis, Granulomatous OR  Enteritis, Regional.
Supplementary Table 1. ????????????
Year
???????????
Year
???????????
UC ?? UC ??
1990 12 3 2002 14 8
1991 11 4 2003 12 8
1992 11 3 2004 15 8
1993 11 5 2005 15 6
1994 10 4 2006 15 12
1995 10 5 2007 14 9
1996 13 8 2008 15 12
1997 11 6 2009 16 16
1998 12 7 2010 16 13
1999 11 12 2011 16 13
2000 13 9 2012 16 14
2001 12 11
???????????????????????????????????????????????????????????????????????????
Supplementary Table 2: ????????????????????????????????????????????????????????????????
671?Record?
excluded
151?duplicates?
removed
826?titles?screened
64?Of?full?text?articles?assessed?for?
eligibility
20?studies?included
28?articles?were?serologic?
and?genetic?studies?and?
excluded
91?Record?excluded155?Abstracts?screened
17?articles?were?case?
control?and?excluded?
4?articles?were?clinical?
trials?and?excluded
5?articles?were?other?type?
of?studies?and?excluded
?1?population?based?+?9?hospital?based?
studies
1320?Records?in?Persian?databases?
590?Abstracts?screened
85?full?text?articles?assessed?for?
eligibility
363?duplicate?
removed
730?Record?
excluded
142?Record?
excluded
1?population?based?+?7?hospital?based?
studies?+?2?reviews
1320?titles?screened
30?articles?were?serologic?
and?genetic?studies?and?
excluded
23?articles?were?case?
control?and?excluded?
17?articles?were?clinical?
trials?and?excluded?
5??articles?were?other?type?
of?studies?and?excluded
977?Records?in?English?databases
IBD?systematic?review
Figure 1. ???????????????????????????????????????????????????
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demonstrated a good correlation between incidence and preva-
lence rates (R2 ???????????????????????????????????????????????-
vious regression, prevalence rates at subnational level could be 
computed.
Our assumption was that IBD rates had spatial and temporal 
correlations between neighboring provinces and during the study 
period. As mentioned before, we had incomplete rates for some of 
the provinces and years. Thus, we needed prediction methods to 
compute these rates in the required time span and at subnational 
level. As demonstrated in supplementary Table 2, the available 
number of provinces for which we had data in each year is very 
few. If we wanted to use usual spatio-temporal models, we would 
???????????????????????????????????????????????????????????-
ponents. Therefore, we decided to use simpler models rather than 
modifying spatio-temporal model components for this study We 
also considered space and time modeling separately.
The spatial correlation was estimated by Kriging model to com-
pute rates at provincial level. The result of Kriging is the expected 
value of the rates based on spatial interpolation methods for rates 
at subnational level for all 31 provinces and the variance is com-
puted for every province in the country accordingly.22,23
The temporal correlation in IBD rates was considered using a 
Gaussian regression process method (GPR), a Bayesian method 
????? ????????????????????? ?????????????????????????????????????
uncertainty intervals over time.24 GPR needs mean function and 
???????????????????? ???????????????????????????????? ?????????????
used a generalized linear model as a mean function that captured 
the relationship between IBD rates and covariates including years 
of schooling, wealth index, urbanization rate, and gastrointesti-
??????????????????????????? ????????????????????????? ????????????
from a household expenditure (HHS) survey for our desired time 
span at subnational level. The number of GI specialists was the 
cumulative number of graduated GI doctorates in each year. The 
covariance function was considered as a temporal correlation in 
IBD rates. The covariance function and standard errors of Kriging 
model for each data point were used to estimate the uncertainty 
interval over time.25
We repeated these methods for estimating the incidence and 
prevalence rates for each IBD subtype. Finally we made IBD rate 
estimates at subnational and national levels for 23 years (1990 
– 2012). To produce total IBD rates, we conducted a simulation 
on UC and CD rates for each time province combination. This 
simulation was done based on a normal distribution with mean 
and standard error of IBD rates in each combination. Using simu-
lations, we drew 2.5 and 97.5 percentile of total IBD rates and 
produced uncertainty interval over time.
 
Ethical Considerations
? ?????????????????????????????? ??????????????????????????????????????
report. The study was approved by the ethical committee of Digestive 
Diseases Research Institute in Tehran University of Medical Science. 
Results
Systematic review
By searching English and Persian databases, we found 2,297 re-
cords of which, 514 were duplicates. A total of 1,401 irrelevant 
titles were excluded and 233 abstracts did not meet the inclusion 
criteria. A total of 149 full texts were chosen and after consider-
ing inclusion and exclusion criteria, we collected 16 case series, 
2 population-based studies, and 2 review articles (Figure 1 and 
Table 1). We also checked the references of two review articles26,27 
??????????????????????? ?????????????????????????????????????????
of Iranian studies. Primary data of four studies were not available. 
??????????????????????????????????????????? ????????????????????
188 IBD cases. Another one was a hospital-based study in 
Kermanshah reporting 85 IBD patients. The third one was a multi-
center study in Ahwaz on 166 IBD cases and the last one was a 
hospital-based study in Hormozgan province. We extracted data 
from these papers considering year of the study, age groups, and 
sex, but we could not merge it with our outpatient data because 
we could not detect the duplicated cases. Two Iranian studies were 
?????????????????????????????????????????????????????????????????
estimated the incidence of UC and CD in Kerman province to be 
4.98 and 0.8 per 100,000, respectively and another one was an 
IBD registry in Shiraz, which only reported the number of IBD 
patients.18,19 Also, two hospital-based studies reported incidence 
??????????????????????????????????????????????????????????????????
et al. in center of Iran reported incidence and prevalence of 3.04 
and 15.5 per 100,000 for UC in Markazi province.28 The second 
by Masoodi, et al. reported incidence of 3.25 per 100,000 for UC 
in Hormozgan province in southern Iran.29
Outpatient data
There were 11,000 IBD patients. A total of 9,269 (84.26%) had 
UC, 1,646 (14.96%) had CD, and 85 had IC. A total of 5,452 pa-
tients (49.56%) were male. The female/male ratios were 1.01 and 
1.06 for UC and CD, respectively. Mean age at diagnosis was 
32.80 year (CI: 13 – 61) for UC and 29.98 year (CI: 11 – 58) for 
???? ????? ????????????????????????????????????????????????????-
lence between women and men. Peak age at diagnosis was in 20-
30 year age group for CD and in 30-40 year age group for UC. 
Incidence
The incidence of IBD increased from 0.62 to 3.11 per 100,000 
from 1990 to 2012. CD and UC incidence increased from 0.19 
to 0.41 and from 0.42 to 2.70 per 100,000 in the study period, 
respectively (Table 2 and Figure 4). UC and CD incidence had a 
????????????????????????????????????????????????????????????????
2.16 for CD: 6.0, P?????????????????????????????????????????????
in incidence between men and women for UC and CD (P-value 
> 0.05). The incidence of IBD was most common in Guilan, Ma-
zandaran, Qazvin, and Tehran with 6.19, 4.24, 4.24 and 3.88 per 
100,000 respectively in 2012 (Table 2). Mean annual incidence 
was calculated for each province and demonstrated in Figure 5.
Prevalence
According to our estimation, the prevalence of IBD increased 
from 4.69 to 40.67 per 100,000 in 1990 to 2012. CD and UC 
prevalence increased from 1.06 to 5.03 and from 3.62 to 35.52 
per 100,000 during the study period, respectively (Table 3 and 
???????????????????????????????????????????????????????????????-
?????????????????????????????????????????????????????????
increases in UC and CD prevalence (prevalence rate ratio for UC: 
9.81 and for CD: 4.74, P < 0.001). IBD was the most prevalent 
in Qazvin, Zanjan, Qom, Semnan, and Guilan with 72.56, 72.30, 
67.32, 65.40, and 64.10 per 100,000, respectively in 2012 (Table 
3 and Figure 7). UC/CD prevalence ratio was 3.41 in 1990, which 
????????????????????????????????????????P < 0.001).
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in Iran.30,31? ???? ????? ??? ??????????? ????????? ??? ?????? ????32,33 
Thereafter, as shown in Table 1, plenty of local studies were done, 
???? ?????????????? ????????????????????????????????????????????????
incidence and prevalence of IBD, as well as its trend in Iran. We 
found that the incidence of IBD, CD, and UC were 3.11, 0.41, and 
2.70 per 100,000 respectively in 2012. Prevalence of IBD, CD, 
and UC were 40.67, 5.03, and 35.52 per 100,000 respectively in 
2012. 
Almost all studies in Middle Eastern countries were hospital-
??????????????????????????????????????????????????????????????-
cidence and prevalence rate. For instance, Abdul-Baki, et al.34 re-
ported a higher incidence rate in Lebanon than Iran (4.9, 1.4, and 
5.5 per 100,000 for UC, CD, and IBD respectively). Also the es-
timated prevalence in Lebanon was much higher than our results 
(159.3 vs. 40.67). In contrary, studies from Oman (1.35/100,000) 
and Kuwait (2.8/100,000) reported incidence rates for UC simi-
201220102005200019951990
UC
??
???
Figure 5.? ???????????????????????????????????????????????????????
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lar to ours.35,36 One study from central Saudi Arabia reported in-
cidence of CD as 0.94 per 100,000, which is higher than what 
we found in our country.37 However, conducting multi-national 
population-based studies for a better estimate of incidence and 
prevalence of IBD and its geographical variation in Middle-East 
is necessary. Such studies have been conducted in Eastern Asia 
and Europe.9,38
The incidence and prevalence of UC and CD has a wide geo-
graphical variation across the world. Incidence of UC ranges from 
0.24 per 100,000 in Thailand (Chiang Mai)38 to 50 per 100,000 in 
the USA.39 Incidence of CD ranges from zero in Greenland9 to 33 
per 100,000 in USA.39 Prevalence of UC in ranges from 2.42 in 
Romania40  to 413 per 100,000 in USA39 and prevalence of CD 
ranges from 1.2 in Sri Lanka41 to 287 per 100,000 in the USA.39 
Summary of recent reports on incidence of IBD across the world 
are demonstrated in Table 5. Our estimated UC prevalence (35.52 
per 100,000) was higher than reported rates from China, Sri Lan-
ka, and Taiwan.41–43 Our estimated UC prevalence was also close 
to Korea and India,44,45 but lower than Japan and New Zealand.46,47 
Our estimated CD prevalence (5.03 per 100,000) was similar to 
other Asian countries, but was less than some eastern countries 
such as Korea.45 In spite of higher reported rates from Western 
Europe, our results were close to reports from Eastern Europe. 
Also, our rates were much lower than that of USA and Canada, 
but similar to central and southern American countries.
The prevalent cases of IBD in Iran based on the global burden 
of diseases (GBD) 2013 study were estimated to be 37,700 and 
108,200 in 1990 and 2013 respectively, with a 9.6% increase in 
age-standardized prevalence rate. This estimation is much higher 
than the reported prevalence of IBD in this study, but the increas-
ing trend is similar. As for IBD subtypes, the GBD study also 
showed a steady trend for UC prevalence and incidence, as well as 
the increasing trend for CD prevalence and incidence from 1990 
to 2013. Due to the limitation in study methodology, we are re-
porting a minimum incidence of IBD in Iran. Therefore, the actual 
IBD incidence and prevalence is higher than what we have report-
ed in this study. A very low UC/CD ratio and a more pronounced 
increasing trend of CD in GBD 2013 study is in fact what is ex-
pected based on the experience from other regions of the world. 
We will most likely observe CD incidence to approach that of UC 
in Iran in near future. Also quite a high number of CD cases may 
be diagnosed as UC at the onset of symptoms until the diagnosis 
of CD becomes established later during the follow-up. The rate of 
?????????????????????????????????????????????????????????????????
of its emergence as shown in the previous reports.32,33 Therefore, 
the possibility that we have underestimated the number of CDs in 
the onset of IBD epidemic in Iran is probably an explanation for 
higher UC/CD ratio in our study.3,5,48,49
?????????????????????????????????????????????????? ?????????????????
in the last two decades corresponding with the experience observed 
in the Western countries more than 50 years ago due to the progres-
sive adoption of modern lifestyle. Also, many studies in developing 
and developed Asian countries such as Korea, Japan, China, Hong 
Kong, Taiwan, and Lebanon, revealed a similar trend.34,42,43,45,46,50 
One of the most important aspects of western lifestyle that explains 
this increase is the western diet characterized by overconsumption 
???????????????????????????????????????????????????????????????????-
?????????????????????????????????????????????????????????????????????
diet which is increasingly consumed in Eastern Europe, Asia and 
Middle East can predispose people to IBD most likely by changing 
the gut microbiota.51–53 Another important aspect of modern life is 
the widespread domestic food refrigeration, which was due to the 
fridge ownership during the second half of the 20th century.54 Other 
proposed reasons were improvement in water supply, sewage, and 
optimal breast feeding.46,51 In parallel, substantial improvement and 
availability of infrastructures such as healthy drinking water, healthy 
waste disposal, better access to electricity and gas has occurred in 
Iran. Urbanization, higher rate of literacy, and better communica-
tions have been substantial. Therefore, increasing incidence of IBD 
was expected in Iran due to these changes in lifestyle and improve-
ment in socioeconomic indices.  
?????? ???????????????????????????????? ????? ?????????????????????
due to better availability of diagnostic facilities and improvement 
of physician knowledge may have contributed to this observa-
tion.11 However, we adjusted our model for number of GI special-
ists across the country during the study period, which showed that 
this increase is not completely dependent on this issue. Moreover, 
the widely observed increasing trend in IBD incidence in other 
developing countries during recent decades highlights the effect 
?????????????????????????????????????????????????????????????
By this increase in incidence, the increasing prevalence of both 
UC and CD is predictable. Additionally, early onset of IBD, better 
care, and reduced mortality of IBD patients will lead to further 
increase in prevalence.7?????? ??? ????????????????????????????? ??-
dicating a 9.81 and 4.75 fold increase in UC and CD prevalence, 
respectively. 
201220102005200019951990
UC
??
???
Figure 7.?????????????????????????????????????????????????
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UC/CD prevalence rate ratio was 3.41 in 1990, which increased 
to 7.06 in 2012, showing that the prevalence of UC is more and 
has a higher pace. In Asia, it was shown that UC is more preva-
lent than CD45,55,56 and one review estimated that the UC/CD ratio 
ranges from 1.2 to 6 in Asia.57 Moreover, UC is more prevalent 
than CD in Scandinavian countries and some East European 
countries, but it was demonstrated that this ratio is diminishing in 
recent years.8,45,57–62 However, in Canada, United States, Australia, 
and other European countries, the prevalence and incidence of CD 
is higher than UC.13,63–69 In western countries, 60 years after the 
emergence of IBD, CD prevalence exceeded that of UC.8,13,70,71 
We expect that the prevalence of CD will increase more rapidly 
and will approach that of UC in the next 20 years.
The main limitation of this study was using non population-
based data. This may lead to underestimation of the incidence and 
prevalence of IBD. Another problem is that we didn’t take into 
account the dead or immigrants for calculating prevalence, which 
may lead to overestimation of the prevalence. The strength of our 
study was collecting the largest number of Iranian IBD patients 
in Iran and Middle East. Also, using GPR and spatial modeling, 
we made better estimations of IBD incidence and prevalence in 
provinces for which we did not have original data and this was 
another strength of our study.
In conclusion, the incidence and prevalence of IBD in Iran are 
growing rapidly in parallel with other developing countries, and 
it will become a major health challenge in near future. Its preva-
lence and incidence were similar with Middle Eastern, Central 
Asian, and East European countries and were less than Eastern 
Asian, Western European, and Northern American countries. The 
prevalence and incidence of both UC and CD were increasing and 
it is expected that CD will surpass UC in forthcoming years. Es-
tablishing a national population-based IBD registry seems to be 
necessary in Iran. 
Authors’ contribution
Masoud M. Malekzadeh: Collecting the data, systematic re-
?????? ????? ?????????? ???????? ???????????????? ?????????? ???? ?-
nal draft; Homayoon Vahedi: Designing the study, conducting 
????????? ???????????? ?????????? ????????????????Kimiya Gohari: 
?????????????????????????????????????????????????????????????????
draft; Parinaz Mehdipour: Statistical analysis, writing the manu-
?????????????????? ????????????????Sadaf G. Sepanlou: Drafting 
the manuscript, commenting on results and discussion; Nasser 
Ebrahimi Daryani: Share cases, commenting on the manuscript; 
Mohammad R. Zali: Share cases, commenting on the manu-
script; Fariborz Mansour-Ghanaei: Share cases, commenting on 
the manuscript; Alireza Safaripour: Share cases, commenting on 
the manuscript; Rahim Aghazadeh: Share cases, commenting on 
the manuscript; Hassan Vossoughinia: Share cases, commenting 
on the manuscript; Hafez Fakheri: Share cases, commenting on 
the manuscript; Mohammad H. Somi: Share cases, commenting 
on the manuscript; Iradj Maleki: Share cases, commenting on the 
manuscript; Vahid Hoseini: Share cases, commenting on the man-
uscript; Mohammad Reza Ghadir: Share cases, commenting on 
the manuscript; Hamed Daghaghzadeh: Share cases, comment-
ing on the manuscript; Hamid Tavakoli: Share cases, commenting 
on the manuscript; Payman  Adibi: Share cases, commenting on 
the manuscript; Alireza Taghavi: Share cases, commenting on the 
manuscript; Mohammad Javad Zahedi: Share cases, comment-
ing on the manuscript; Taghi Amiriani: Share cases, comment-
ing on the manuscript; Masoud Tabib: Share cases, commenting 
on the manuscript; Zainab Alipour: Share cases, commenting 
on the manuscript; Ahmad Arab: Share cases, commenting on 
the manuscript; Hossein Nobakht: Share cases, commenting on 
the manuscript; Abbas Yazdanbod: Share cases, commenting on 
the manuscript; Masoud Sadreddini: Share cases, commenting 
on the manuscript; Alireza Bakhshipour: Share cases, comment-
ing on the manuscript; Ahmad Khosravi: Share cases, comment-
ing on the manuscript; Pejman Khosravi: Collecting the data, 
?????????? ???? ????? ??????? Siavosh Naserimoghadam: Share 
cases, commenting on the manuscript; Shahin Merat: Share 
cases, commenting on the manuscript; Rasoul Sotoodehmanesh: 
Share cases, commenting on the manuscript; Farhad Barazan-
deh: Share cases, commenting on the manuscript; Peyman Arab: 
Share cases, commenting on the manuscript; Nadieh Baniasadi: 
Share cases, commenting on the manuscript; Seyyed Javad Pour-
naghi: Share cases, commenting on the manuscript; Mahboubeh 
Parsaeian: Study design, statistical analysis, commenting on the 
manuscript; Farshad Farzadfar: Study design, statistical analy-
sis, commenting on the manuscript; Reza Malekzadeh: Study de-
?????????????????????????????????????????????????????????????????
???????????
Competing Interest: ???????????????????????????????????????
Ethical approval: not needed
Acknowledgments
We acknowledge all medical students and health staff who 
helped us for gathering data. We thank the Iranian Association of 
Gastroenterology and Hepatology for logistic support.
References
1. Everhart JE, Ruhl CE. Burden of digestive diseases in the United 
States part II:  lower gastrointestinal diseases. Gastroenterology. 2009; 
136: 741 – 754.
2. Everhart JE, Ruhl CE. Burden of digestive diseases in the United 
States part I:  overall and upper gastrointestinal diseases. Gastroenter-
ology. 2009; 136: 376 – 386.
3. Global, regional, and national incidence, prevalence, and years lived 
with disability for 301 acute and chronic diseases and injuries in 188 
countries, 1990 – 2013:  A systematic analysis for the Global Burden 
of Disease Study 2013. Lancet. 2015; 386: 743-800.
4. Global, regional, and national disability–adjusted life years (DALYs) 
for 306 diseases and injuries and healthy life expectancy (HALE) for 
188 countries, 1990 – 2013:  quantifying the epidemiological transi-
tion. Lancet. 2015; 386: 2145-2191.
5. ???????????????????????????????????????????????????????????????????
???????? ???????????????????????????????????????????????? ????????????
analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 
385: 117 – 171.
6. Kappelman MD, Rifas–Shiman SL, Porter CQ, Ollendorf DA, Sandler 
RS, Galanko JA, et al. Direct health care costs of Crohn’s disease and 
ulcerative colitis in US children and adults. Gastroenterology. 2008; 
135: 1907 – 1913.
7. ??????????????????? ????????? ???????????????????????????????????-
tory bowel disease in Europe. J Crohns Colitis. 2013; 7: 322 – 337.
8. Cosnes J, Gower–Rousseau C, Seksik P, Cortot A. Epidemiology and 
???????? ???????? ??? ???????????? ?????? ????????. Gastroenterology. 
2011; 140: 1785 – 1794.
9. Burisch J, Pedersen N, Cukovic–Cavka S, Brinar M, Kaimakliotis I, 
?????????????????????????????????????????????????????????????????-
tory bowel disease in Europe:  the ECCO–EpiCom inception cohort. 
Archives of Iranian Medicine, Volume 19, Number 1, January 201614
?????? ????? ??? ??????????????????????????????
Gut. 2014; 63: 588 – 597.
10. Nguyen GC, Chong CA, Chong RY. National estimates of the burden 
???????????????????????????????????????????????????????????????????
United States. J Crohns Colitis. 2014; 8: 288 – 295.
11. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, 
????????????????????????????????????????????????????????????????????
diseases with time, based on systematic review. Gastroenterology. 
2012; 142: 46 – 54.e42; quiz e30.
12. ??????? ?? ????? ??????? ??? ???????????????????????????????????
bowel disease in eastern Canada:  a population database study. BMC 
Gastroenterol. 2014; 14: 140.
13. Molinie F, Gower–Rousseau C, Yzet T, Merle V, Grandbastien B, 
Marti R, et al. Opposite evolution in incidence of Crohn’s disease and 
ulcerative colitis in Northern France (1988 – 1999). Gut. 2004; 53: 
843 – 848.
14. Loftus CG, Loftus EV, Jr., Harmsen WS, Zinsmeister AR, Tremaine 
WJ, Melton LJ, 3rd, et al. Update on the incidence and prevalence of 
Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 
1940 – 2000. ????????????? ??? 2007; 13: 254 – 261.
15. ???????????? ???? ??? ?? ???????? ???????? ??????????????????
bowel disease in Asia:  a systematic review. J Gastroenterol Hepatol. 
2012; 27: 1266 – 1280.
16. Ouyang Q, Tandon R, Goh KL, Ooi CJ, Ogata H, Fiocchi C. The 
?????????????????????????????????????????????? ??????????????????. 
Curr Opin Gastroenterol. 2005; 21: 408 – 413.
17. ??????????????????????????????????????????????????????????????????-
ry bowel disease changing in Eastern Europe? Scand J Gastroenterol. 
2006; 41: 870 – 871; author reply 871 – 872.
18. ???????? ????????????????????????????????????????????????????????-
tory bowel diseases in Fars province, Iran. Middle East Journal of 
Digestive Diseases. 2012; 4: 97 – 101.
19. Zahedi MJ, Darvish Moghadam S, Hayat Bakhsh Abbasi M, Deh-
?????? ?????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????
country. Middle East J Dig Dis. 2014; 6: 32 – 36.
20. Naghavi M, Abolhassani F, Pourmalek F, Lakeh M, Jafari N, Vaseghi 
S, et al. The burden of disease and injury in Iran 2003. Popul Health 
Metr. 2009; 7: 9.
21. Salimzadeh H, Ardeshir Larijani F, Abedian S, Kalantar Motamedi 
SM, Malekzadeh MM, Mohaghegh H, et al. The trend of national and 
sub–national burden of gastrointestinal and liver diseases in Iran 1990 
to 2013; study protocol. Arch Iran Med. 2014; 17: 33 – 53.
22. Le Riche R, Introduction to kriging. 2014.
23. Stein ML, Interpolation of spatial data:  some theory for kriging. 
1999, Springer–Verlag New York.
24. Rasmussen CE, Gaussian Processes for Machine Learning. 2006, the 
MIT Press:  Massachusetts Institute of Technology.
25. Mehdipour P, Navidi I, Parsaeian M, Mohammadi Y, Moradi Lakeh 
M, Rezaei Darzi E, et al. Application of Gaussian Process Regres-
??????????????????????????????????? ???????????????????????????????????
1990  –  2013, study protocol. Arch Iran Med. 2014; 17: 189 – 192.
26. ?????????????????????????????????????????????????????????????-
matory bowel diseases in Iran and Asia; A mini review. Iranian Jour-
nal of Medical Sciences. 2013; 38: 140 – 149.
27. ?????????? ??????????????? ?? ??????????????????????? ??????????-
logical, Demographic, and Colonic Extension ofUlcerative Colitis in 
Iran:  A Systematic Review. Middle East J Dig Dis. 2013; 5: 29 – 36.
28. ?????????????????????????????????????????????????????????????????
disease and its clinical presentation in Arak. Arak Medical University 
Journal (Rahavard Danesh) 2002; 5: 23 – 28.
29. Masoodi M, Agah S, Kashani AHF, Eghbali H. Estimation of ulcer-
ative colitis incidence in hormozgan province, Southern Iran. Gova-
resh. 2011; 16: 265 – 269.
30. Mir – Madjlessi SH, Forouzandeh B, Ghadimi R. Ulcerative colitis in 
Iran:  a review of 112 cases. Am J Gastroenterol. 1985; 80: 862 – 866.
31. Malekzadeh R. Ulcerative colitis in southem Iran:  A review of 64 
cases. Iranian journal od medicine. 1986; 13: 54 – 59.
32. Malekzadeh R, Mirmadjlesi H, Varshoesaz J, Agah S, Tavakoli H. Ris-
ing the incidence of Crohn’s disease in Iran during last decade(1989 
– 1999). Gastroenterology. 2000; 118: A1356 – A1356.
33. Malekzadeh R VJ, Merat S, Hadidchi S, Mir Majlesi SH, Vahedi H, 
Radmehr A, Soroush Z, Tavakkoli H, Agah S, Kamalian N, Hormozdi 
M, Maghazei A, Vahid AA. Crohn’s disease:  A review of 140 cases 
from Iran. Iranian Journal of Medical Sciences. 2000; 25: 138 – 143.
34. Abdul–Baki H, ElHajj I, El–Zahabi LM, Azar C, Aoun E, Zantout H, 
?????????????????????????????????????????????????????????????????-
non. ????????????? ??? 2007; 13: 475 – 480.
35. Al–Shamali MA, Kalaoui M, Patty I, Hasan F, Khajah A, Al–Nakib B. 
Ulcerative colitis in Kuwait:  a review of 90 cases. Digestion. 2003; 
67: 218 – 224.
36. Radhakrishnan S, Zubaidi G, Daniel M, Sachdev GK, Mohan AN. 
Ulcerative colitis in Oman. A prospective study of the incidence and 
disease pattern from 1987 to 1994. Digestion. 1997; 58: 266 – 270.
37. ?????????????????????????????????????????????????????????-
breen AM, Isnani AC, et al. Epidemiology and outcome of Crohn’s 
disease in a teaching hospital in Riyadh. World J Gastroenterol. 2004; 
10: 1341 – 1344.
38. Ng SC, Tang W, Ching JY, Wong M, Chow CM, Hui AJ, et al. Inci-
????????????????????????????????????????????????????????????-
??????????????? ?????????????????????????????????????????????????. 
Gastroenterology. 2013; 145: 158 – 165.
39. Hou JK, Kramer JR, Richardson P, Mei M, El–Serag HB. The in-
?????????????????????????? ?????????????????????????????????????
veterans:  a national cohort study. ????????????? ??? 2013; 19: 1059 
– 1064.
40. Gheorghe C, Pascu O, Gheorghe L, Iacob R, Dumitru E, Tantau M, et 
??????????????????????????????????????????????????????????????????
to gastroenterology care in Romania:  A multicentre study. Eur J Gas-
troenterol Hepatol. 2004; 16: 1153 – 1159.
41. Niriella MA, De Silva AP, Dayaratne AH, Ariyasinghe MH, Na-
????????????? ??????? ???? ??? ???? ??????????? ??? ???????????? ??????
disease in two districts of Sri Lanka:  a hospital based survey. BMC 
Gastroenterol. 2010; 10: 32.
42. Lok KH, Hung HG, Ng CH, Kwong KC, Yip WM, Lau SF, et al. Epi-
demiology and clinical characteristics of ulcerative colitis in Chinese 
population:  experience from a single center in Hong Kong. J Gastro-
enterol Hepatol. 2008; 23: 406 – 410.
43. Wei SC, Lin MH, Tung CC, Weng MT, Kuo JS, Shieh MJ, et al. A 
????????????????????????????????????????????????????????????????-
eases between 1998 and 2008 in Taiwan. BMC Gastroenterol. 2013; 
13: 166.
44. Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and preva-
lence of ulcerative colitis in Punjab, North India. Gut. 2003; 52: 1587 
– 1590.
45. Yang SK, Yun S, Kim JH, Park JY, Kim HY, Kim YH, et al. Epide-
??????????? ????????????????????????????? ??????????????????????
district, Seoul, Korea, 1986 – 2005:  a KASID study. ?????????????
Dis. 2008; 14: 542 – 549.
46. Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi 
T. Prevalence of ulcerative colitis and Crohn’s disease in Japan. J Gas-
troenterol. 2009; 44: 659 – 665.
47. Gearry RB, Richardson A, Frampton CM, Collett JA, Burt MJ, Chap-
man BA, et al. High incidence of Crohn’s disease in Canterbury, New 
Zealand:  results of an epidemiologic study. ??????? ????? ??? 2006; 
12: 936 – 943.
48. Malekzadeh R Global Burden of Disease Study 2010:  A real advance 
in global descriptive epidemiology:  prospective for developing coun-
tries. Arch Iran Med. 2014; 17: 302 – 303.
49.  Epi Visualization?? ????? ? ??????? ????? ???????????? ?????????? ??????
URL:  http: //vizhub.healthdata.org/epi/.
50. Jiang L, Xia B, Li J, Ye M, Yan W, Deng C, et al. Retrospective survey 
?????????????????????????????????????????????????? ??????????????-
tral China. ????????????? ??? 2006; 12: 212 – 217.
51. ??????????????? ?????????????????????????????????????????????
in Asia. J Gastroenterol Hepatol. 2010; 25: 436 – 8.
52. Hou JK, Abraham B, El–Serag H Dietary intake and risk of develop-
?????????????????????????????????????????????????????????????????????. 
Am J Gastroenterol. 2011; 106: 563 – 573.
53. Sakamoto N, Kono S, Wakai K, Fukuda Y, Satomi M, Shimoyama T, 
???????????????????????????????? ??????????????????????????? ????????-
center case–control study in Japan. ???????????????? 2005; 11: 154 
– 163.
54. Malekzadeh F, Alberti C, Nouraei M, Vahedi H, Zaccaria I, Meinzer 
U, et al. Crohn’s Disease and Early Exposure to Domestic Refrigera-
tion. PLoS One. 2009; 4.
55. Thia KT, Loftus EV, Jr., Sandborn WJ, Yang SK. An update on the 
????????????????????????????????????????????? ???. Am J Gastroen-
terol. 2008; 103: 3167 – 3182.
56. ????? ??? ?????? ?? ?? ???????????????????????????????????????-
ease in China. J Dig Dis. 2010; 11: 76 – 82.
57. ???????????????????????????????????????????????????????????? ???. 
Best Pract Res Clin Gastroenterol. 2014; 28: 363 – 372.
Archives of Iranian Medicine, Volume 19, Number 1, January 2016 15
??? ?? ?? ?????????????????????? ??????????????
58. Lakatos L, Kiss LS, David G, Pandur T, Erdelyi Z, Mester G, et al. 
Incidence, disease phenotype at diagnosis, and early disease course 
??? ??????????????????????????? ???????????????????????????????. 
????????????? ??? 2011; 17: 2558 – 2565.
59. Jussila A, Virta LJ, Salomaa V, Maki J, Jula A, Farkkila MA. High 
??????????????????????????????????????????????????????????????????
with a clear North–South difference. J Crohns Colitis. 2013; 7: e256 
– e262.
60. Fonager K, Sorensen HT, Olsen J. Change in incidence of Crohn’s 
disease and ulcerative colitis in Denmark. A study based on the Na-
tional Registry of Patients, 1981 – 1992. Int J Epidemiol. 1997; 26: 
1003 – 1008.
61. Tsianos EV, Masalas CN, Merkouropoulos M, Dalekos GN, Logan 
?????????????????????????????????????????????????????????????????
rarity of Crohn’s disease in an area where ulcerative colitis is common. 
Gut. 1994; 35: 369 – 372.
62. Wiercinska–Drapalo A, Jaroszewicz J, Flisiak R, Prokopowicz D. Ep-
????????????????????????????????????????????????????????????????????
– Eastern Poland. World J Gastroenterol 2005; 11: 2630 – 2633.
63. ??????????????? ?????????????????????? ???????? ??? ????????-
????????????????????????????????????????????????????. Eur J Gastro-
enterol Hepatol. 1999; 11: 543 – 546.
64. Sincic BM, Vucelic B, Persic M, Brncic N, Erzen DJ, Radakovic B, et 
?????????????????????????????????????????????????????????????????
County, Croatia, 2000 – 2004:  A prospective population–based study. 
Scand J Gastroenterol. 2006; 41: 437 – 444.
65. Kappelman MD, Rifas–Shiman SL, Kleinman K, Ollendorf D, Bous-
varos A, Grand RJ, et al. The prevalence and geographic distribution 
of Crohn’s disease and ulcerative colitis in the United States. Clin 
Gastroenterol Hepatol. 2007; 5: 1424 – 1429.
66. Shivananda S, Lennard–Jones J, Logan R, Fear N, Price A, Carpenter 
????????????????????????????????????????????????????????????????????
there a difference between north and south? Results of the European 
????????????????????????????????????????? ???????????????. Gut. 
1996; 39: 690 – 697.
67. Declercq C, Gower–Rousseau C, Vernier–Massouille G, Salleron J, 
?????? ???????????????????? ???????????????????????????????????????
?????????????????????????????????????????????????????????????. ???????
Bowel Dis. 2010; 16: 807 – 812.
68. Wilson J, Hair C, Knight R, Catto–Smith A, Bell S, Kamm M, et al. 
????? ????????????? ?????????????????????????? ?????????????? ??????-
spective population–based Australian incidence study. ?????????????
Dis. 2010; 16: 1550 – 1556.
69. Cottone M, Renda MC, Mattaliano A, Oliva L, Fries W, Criscuoli V, 
et al. Incidence of Crohn’s disease and CARD15 mutation in a small 
township in Sicily. Eur J Epidemiol. 2006; 21: 887 – 892.
70. Ekbom A, Helmick C, Zack M, Adami HO. The epidemiology of in-
????????????????????????????????????????????????????????????????-
den. Gastroenterology. 1991; 100: 350 – 358.
71. Makharia GK. Rising incidence and prevalence of Crohn’s disease in 
Asia:  is it apparent or real? J Gastroenterol Hepatol. 2006; 21: 929 
– 931.
72. Ebrahimi Daeiani N MH, Airamloo M. Clinical and epidemiological 
characteristics in ulcerative colitis patients referred to Imam Hospital, 
1995 – 2000. The Journal of Tehran Faculty of Medicine. 2001; 59(4): 
80 – 85.
73. Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F. 
?????????????????????????????????????????????????????????. J Gastro-
enterol Hepatol. 2005; 20: 1691 – 1695.
74. ????????????????????????????????????????????????????????????????-
view of 302 Patients. Govaresh, Iranian Association of Gastroenterol-
ogy And Hepatology. 2007; 12: 155 – 160.
75. Keshavarz AAI. Frequency of Colonic Extension by Colonoscopy in 
Ulcerative Colitis Patients in Kermanshah Province in the Years 2002 
– 200. ??????????????????????? ????????? 2008; 11: 441 – 449.
76. Masjedi zadeh RHE, Hashemi SJ, Azmi M, Shayesteh Ak. Epidemio-
?????????????????????????????????????? ?????????? ????????. Scien-
????? ?????????????????????????????????????? ?????????????????2007; 
6: 54 – 63.
77. Darakhshan F, Vali Khojeini E, Balaii H, Naderi N, Firouzi F, Farnood 
?????????????????????????? ?????????????????????????? ??? ?????? ???
review of 803 cases. Gastroenterology and Hepatology from Bed to 
Bench. 2008; 1: 19 – 24.
78. Vahedi H, Merat S, Momtahen S, Olfati G, Kazzazi AS, Tabrizian T, 
????????????????????????????????????????????????????? ????????????????
bowel disease in Iran studied from 2004 through 2007. Arch Iran Med. 
2009; 12: 454 – 460.
79. Zahedi MJ, Darvish–moghadam S, Haiatbakhsh M, Dalirsani Z De-
mographic and Clinical Features of Ulcerative Colitis Patients in Ker-
man City during 2005 – 2007. Journal of Kerman University of Medi-
cal Sciences. 2009; 16: 45 – 53.
80. Ghadir MRSS. Colonoscopic Diagnostic Findings in Patients Un-
dergoing Colonoscopy In Qom Hazrat–e–Masoome Hospital During 
2007 – 2008. ???????????????????????????????????????????????2011; 
5(2):  64 – 69.
81. Yazdanbod A, Farzaneh E, Pourfarzi F, Azami A, Mostafazadeh B, 
??????????????????????????????????????????????????????????????????????
ulcerative colitis in northwest of Iran:  a 10 – year review. Trop Gas-
troenterol. 2010; 31: 308 – 311.
82. Shirazi KM, Somi MH, Bafandeh Y, Saremi F, Mylanchy N, Rezaeifar 
??????????????????????????????????????????????????????????????????????
bowel disease in patients from northwestern iran. Middle East J Dig 
Dis. 2013; 5: 86 – 92.
83. Taghavi S, Sarfarpour A, Hosseini S, Noruzi H, Safarpour M, Rahimi-
????????????????????????????????????????????????????????????????
Iran:  A review of 740 patients in Fars province, southern Iran. Annals 
of Colorectal Research. 2013; 1: 17 – 22.
84. ????????? ??? ?????? ????????????????????????????????????? ???????
presentation and initial management. J Gastroenterol Hepatol. 1998; 
13: 1119 – 1124.
85. ???????? ????????? ???????????????????????????????????? ???????
Saudi Arabia. Saudi Med J. 2009; 30: 537 – 540.
86. ???????????? ??? ??????????????????????????????????????????-
ease in saudi outpatients:  a report of 693 cases. Saudi J Gastroenterol. 
2013; 19: 16 – 22.
87. Aljebreen AM, Alharbi OR, Azzam NA, Almalki AS, Alswat KA, 
Almadi MA. Clinical epidemiology and phenotypic characteristics of 
Crohn’s disease in the central region of Saudi Arabia. Saudi J Gastro-
enterol. 2014; 20: 162 – 169.
88. Betteridge JD, Armbruster SP, Maydonovitch C, Veerappan GR. In-
???????????????????????? ??????????? ???????????????? ?????? ????
Geographic Location in the US Military Health Care Population. In-
???????????????? ???????? 2013; 19: 1421 – 1427.
89. Yang H, Li Y, Wu W, Sun Q, Zhang Y, Zhao W, et al. The incidence of 
????????????????????????????? ???????? ???????????????????????????-
tion–based study. PLoS One. 2014; 9: e101296.
